UniProt P54753 · PDB · AlphaFold · Substrate: pEY · Clone: cytoplasmichigh-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Dasatinib | 98.5% | 1.5% | 87.97 | 0.699 |
| 2 | Ponatinib | 97.9% | 2.1% | 78.23 | 0.534 |
| 3 | Nilotinib | 89.9% | 10.1% | 96.49 | 0.765 |
| 4 | Repotrectinib | 86.2% | 13.8% | 84.21 | 0.608 |
| 5 | Bosutinib | 84.0% | 16.0% | 87.22 | 0.555 |
| 6 | Ripretinib | 64.4% | 35.6% | 92.95 | 0.674 |
| 7 | Tivozanib | 45.1% | 54.9% | 92.42 | 0.673 |
| 8 | Cabozantinib | 36.8% | 63.2% | 92.73 | 0.751 |
| 9 | Erdafitinib | 21.3% | 78.7% | 95.71 | 0.737 |
| 10 | Gilteritinib | 13.3% | 86.7% | 88.97 | 0.506 |
| 11 | Nintedanib | 13.0% | 87.0% | 90.23 | 0.608 |
| 12 | Lorlatinib | 11.8% | 88.2% | 97.24 | 0.694 |
| 13 | Crizotinib | 10.9% | 89.1% | 91.39 | 0.581 |
| 14 | Neratinib | 10.4% | 89.6% | 93.18 | 0.597 |
| 15 | Capmatinib | 9.4% | 90.6% | 99.75 | 0.582 |
| 16 | Apatinib | 9.3% | 90.8% | 97.73 | 0.704 |
| 17 | Pirtobrutinib | 9.2% | 90.8% | 99.49 | 0.656 |
| 18 | Vandetanib | 9.0% | 91.0% | 95.74 | 0.723 |
| 19 | Pacritinib | 8.6% | 91.4% | 88.64 | 0.452 |
| 20 | Upadacitinib | 8.5% | 91.5% | 97.98 | 0.663 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.78
- Epithelial log2(TPM+1): 2.82
- Fold change: -1.03
- Status: Downregulated
High-confidence drugs
- Dasatinib — inh 98.5% · KISS 40.62
- Nilotinib — inh 89.9% · KISS 39.63
- Ponatinib — inh 97.9% · KISS 30.10
Selectivity landscape vs inhibition on EPHB3
Each point is one of the 92 approved drugs; color = inhibition % on EPHB3.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…